|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Showing grants 1 to 10 of 105 | | A Novel Antimicrobial Delivery System | | George O'Toole, Dartmouth College, United States - US |
| | | Drugs | George O’Toole, a microbiologist at Darmouth Medical School, and Mark Grinstaff, a biomedical engineer and chemist at Boston University, will work to develop an expansile nanoparticle, packed with high concentrations of antibiotics, which would expand and release their content when internalized by host cells. The hope is that more precise delivery of high concentrations of antimicrobial agents, in single or combination therapies, will reduce the development of resistance. |
| | A Novel Structure-Based Model for the Prediction and Exploitation of Resistance Mutations | | Ryan Lilien, University of Toronto, Canada - CA |
| | | Research Tool | Dr. Ryan Lilien of the University of Toronto in Canada will work to computationally model the structural and functional effects of point mutations on a target protein's active site. With the development of predictive models of pathogen evolution and the spread of resistance, this information can be used to guide drug development and optimization.
|
| | Antagonist of RNA-Protein Interactions as Activators of A3G | | Harold Smith, University of Rochester, United States - US |
| | | Drugs | A3G, protein found in human cells that inactivates several viruses including HIV, is "switched off" in proliferating T cells. Harold Smith of the University of Rochester will screen for small molecule compounds that bind to A3G in cells and turn its anti-viral activity back on. |
| | Anti-Mycrobacterials Mycobactin-Linked Glyconanoparticles | | Graham Rook, University College London, United Kingdom - GB |
| | | Drugs | Graham Rook of University College London will target an essential bacterial nutrient transport system with an iron-binding nanoparticle. The particle will be designed not only to block the pore and prevent it from taking in needed nutrients, but to also carry antibiotics that can be released in the vicinity of the bacterium. |
| | Design and Setting-up of a Bioinformatics Platform Dedicated to HIV Drug Resistance Problems | | Ouwe Missi Oukem Odile, Centre International de Reference Chantal Biya, Cameroon - CM |
| | | Drugs | Odile Ouwe Missi Oukem of Cameroon’s Centre International de Reference Chantal Biya will set up a suite of computer tools to manage and analyze biological, clinical and epidemiological data collected from African HIV-infected patients to better study HIV resistance to antiretroviral drugs. |
| | Developing Bdellovibrio as Living Antibiotics | | Renee Elizabeth Sockett, University of Nottingham, United Kingdom - GB |
| | | Vaccines | | The bacteria Bdellovibrio -- harmless to humans -- naturally kill a wide range of gram-negative pathogens which are known to cause many infections. Professor Liz Sockett of the University of Nottingham in England will study whether these pathogens have the ability to form resistance to Bdellovibrio, and if Bdellovibrio can be delivered to patients as a living antibiotic. |
| | Drugs That Invert Selection for Resistance | | Roy Kishony, Harvard , United States - US |
| | | Drugs | Roy Kishony of Harvard University will seek to identify chemical entities that act as “selection inverters” which actively target antibiotic-resistant bacteria. Selection-inverters could be used in combination with traditional antibiotics to prevent resistance and possibly even drive a drug-resistant bacteria population back to drug sensitivity. |
| | Drugs That Target Multiple Receptors for Anthelmintics | | Timothy Geary, McGill University, Canada - CA |
| | | Drugs | Timothy Geary at McGill University in Canada will establish drug screening centers at the universities of Botswana and Capetown, South Africa, where researchers can take advantage of the chemical and biological diversity found in Africa to identify lead compounds to use against local diseases, including parasitic nematodes. |
| | Engineering High Affinity, Broadly Specific T cell Receptors to Target HIV-1 Variants | | Marilyn Fernandez, Altor Bioscience Corporation, United States - US |
| | | Vaccines | | Marilyn Fernandez of Altor Bioscience Corporation in the U.S. will engineer single chain T cell receptors (TCR) to deliver immunotherapies to HIV-infected cells. These TCRs will be engineered to recognize known viral variants to linked to the emergence of drug-resistant HIV mutations. |
| | Gene Locking: Sequence-Specific Targeting of Mycobacterium Tuberculosis | | Samantha Sampson, Imperial College London, United Kingdom - GB |
| | | Drugs | Samantha Sampson of Imperial College London proposes introducing short strands of modified DNA into tuberculosis cells for direct and highly specific targeting of DNA sequences. If successful, it will effectively “lock” DNA, obstruct replication and transcription, and prevent bacterial growth and survival. |
|
1
- 10  |
|
|
|
|
|
|
|